MiNK Therapeutics Q2 loss narrows on expense discipline

Mink Therapeutics

13/08/2026 12:40

Overview
US biopharma firm's Q2 net loss narrowed yr/yr, reflecting continued expense discipline
Company advanced lead cell therapy agenT-797 into randomized Phase 2 trial for acute lung injury
International paid named-patient access program for agenT-797 launched, generating program revenue

Outlook
Company expects additional data from the randomized Phase 2 trial in early 2027
MiNK is expanding patient enrollment for its trial in Ukraine and activating U.S. clinical centers
Company is establishing international access infrastructure through a paid named-patient program in Brazil

Result Drivers
PHASE 2 TRIAL PROGRESS - Co advanced agenT-797 into randomized Phase 2 trial for acute lung injury and ARDS, with initial patients showing clinical improvement and no major serious adverse events
NAMED-PATIENT ACCESS REVENUE - Paid international named-patient access program for agenT-797 launched, providing program revenue and building cross-border infrastructure
TRANSLATIONAL DATA - Early clinical and biological data indicated reduced inflammatory markers and signs of immune recovery and tissue repair following agenT-797 administration

Company press release: ID:nGNX1HBfhs

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
$0.62
 
Q2 Net Loss
 
$3.10 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Mink Therapeutics Inc is $39.00, about 243.3% above its August 12 closing price of $11.36

Reuters Recommended Reads
Aug 10 - Cell therapy developer ProKidney's Q2 operating loss widens as trial costs rise
Aug 12 - Century Therapeutics Q2 net loss misses estimates on lease termination loss
Aug 10 - Sana Biotechnology Q2 adjusted loss narrows, beats estimates

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)